{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:00:21Z","timestamp":1791291621888,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":4266,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1111\/j.1538-7836.2011.04202.x","type":"journal-article","created":{"date-parts":[[2011,1,20]],"date-time":"2011-01-20T11:32:04Z","timestamp":1295523124000},"page":"689-699","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["T\u2010cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site"],"prefix":"10.1016","volume":"9","author":[{"given":"E.A.","family":"JAMES","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.D.","family":"VAN HAREN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"ETTINGER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"FIJNVANDRAAT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"LIBERMAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.W.","family":"KWOK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"VOORBERG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.P.","family":"PRATT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0010","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00062752-199502050-00007","article-title":"Factor VIII Inhibitors","volume":"2","author":"Hoyer","year":"1995","journal-title":"Curr Opin Hematol"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0015","first-page":"2428","article-title":"A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group","volume":"83","author":"Bray","year":"1994","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0020","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1055\/s-2002-32664","article-title":"Inhibitor development in previously untreated patients with hemophilia A: a prospective long\u2010term follow\u2010up comparing plasma\u2010derived and recombinant products","volume":"28","author":"Kreuz","year":"2002","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0025","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1046\/j.1365-2516.1998.440558.x","article-title":"Factor VIII inhibitors in mild and moderate\u2010severity haemophilia A","volume":"4","author":"Hay","year":"1998","journal-title":"Haemophilia"},{"issue":"S3","key":"10.1111\/j.1538-7836.2011.04202.x_bb0030","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2516.2008.01730.x","article-title":"Mild\/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development","volume":"14","author":"d\u2019Oiron","year":"2008","journal-title":"Haemophilia"},{"issue":"S6","key":"10.1111\/j.1538-7836.2011.04202.x_bb0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2516.2006.01361.x","article-title":"Genetic risk factors for inhibitors to factors VIII and IX","volume":"12","author":"Oldenburg","year":"2006","journal-title":"Haemophilia"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0040","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2516.2004.01011.x","article-title":"HLA class II genotype and factor VIII inhibitors in mild haemophilia A patients with an Arg593 to Cys mutation","volume":"10","author":"Bril","year":"2004","journal-title":"Haemophilia"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0045","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1182\/blood.V90.5.1902","article-title":"Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg593 to Cys mutation","volume":"90","author":"Thompson","year":"1997","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0050","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1538-7836.2009.03357.x","article-title":"Intensive peri\u2010operative use of factor VIII and the Arg593 \u2192 Cys mutation are risk factors for inhibitor development in mild\/moderate hemophilia A","volume":"7","author":"Eckhardt","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0055","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood.V95.2.558","article-title":"Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes","volume":"95","author":"van den Brink","year":"2000","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0060","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1182\/blood.V69.5.1475.1475","article-title":"FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting","volume":"69","author":"Fulcher","year":"1987","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0065","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1532\/IJH97.05160","article-title":"Characterization of factor VIII inhibitors","volume":"83","author":"Shima","year":"2006","journal-title":"Int J Hematol"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0070","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1568-9972(01)00017-9","article-title":"Autoantibodies to factor VIII","volume":"1","author":"Lacroix\u2010Desmazes","year":"2002","journal-title":"Autoimmun Rev"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0075","first-page":"35","article-title":"Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors","volume":"85","author":"Ewenstein","year":"2000","journal-title":"Haematologica"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0080","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ajh.2830420408","article-title":"Loss of high\u2010responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the Multi\u2010Center Hemophilia Cohort Study","volume":"42","author":"Bray","year":"1993","journal-title":"Am J Hematol"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0085","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood-2002-05-1369","article-title":"CD4+ T\u2010cell clones specific for wild\u2010type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild\/moderate hemophilia A","volume":"101","author":"Jacquemin","year":"2003","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0090","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1111\/j.1538-7836.2007.02762.x","article-title":"T\u2010cell Responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self\u2010peptide","volume":"5","author":"James","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0095","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2516.2008.01905.x","article-title":"HLA\u2010DR\u2010restricted T\u2010cell responses to Factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P","volume":"16","author":"Ettinger","year":"2010","journal-title":"Haemophilia"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0100","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1182\/blood.V93.7.2267","article-title":"Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A","volume":"93","author":"Peerlinck","year":"1999","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0105","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1182\/blood-2003-04-1321","article-title":"Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development","volume":"103","author":"d\u2019Oiron","year":"2004","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0110","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood.V95.1.156","article-title":"A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor","volume":"95","author":"Jacquemin","year":"2000","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0115","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1111\/j.1538-7836.2004.00918.x","article-title":"T cell recognition of the A2 domain of coagulation factor VIII in hemophilia patients and healthy subjects","volume":"2","author":"Hu","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0120","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1055\/s-0037-1615873","article-title":"CD4+ T cell response to factor VIII in hemophilia A, acquired hemophilia and healthy subjects","volume":"82","author":"Reding","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0125","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/j.1538-7836.2005.01309.x","article-title":"Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII","volume":"3","author":"Jones","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0130","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1055\/s-0037-1614081","article-title":"Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects","volume":"84","author":"Reding","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0135","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1182\/blood.V89.12.4371","article-title":"The missense mutation Arg593 \u2192 Cys is related to antibody formation in a patient with mild hemophilia A","volume":"89","author":"Fijnvandraat","year":"1997","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0140","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1046\/j.1365-2141.2002.03856.x","article-title":"Analysis of factor VIII inhibitors in a haemophilia A patient with an Arg593 \u2192 Cys mutation using phage display","volume":"119","author":"Bril","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0145","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/bioinformatics\/17.12.1236","article-title":"ProPred: prediction of HLA\u2010DR binding sites","volume":"17","author":"Singh","year":"2001","journal-title":"Bioinformatics"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0150","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/BF02199809","article-title":"Natural peptides isolated from Gly86\/Val86\u2010containing variants of HLA\u2010DR1, \u2010DR11, \u2010DR13, and \u2010DR52","volume":"43","author":"Verreck","year":"1996","journal-title":"Immunogenetics"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0155","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1016\/j.molimm.2007.12.013","article-title":"Definition of the peptide binding motif within DRB1*1401 restricted epitopes by peptide competition and structural modeling","volume":"45","author":"James","year":"2008","journal-title":"Mol Immunol"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0160","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1172\/JCI8476","article-title":"MHC class II tetramers identify peptide\u2010specific human CD4(+) T cells proliferating in response to influenza A antigen","volume":"104","author":"Novak","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0165","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/intimm\/dxm099","article-title":"Tetramer\u2010guided epitope mapping reveals broad, individualized repertoires of tetanus toxin\u2010specific CD4+ T cells and suggests HLA\u2010based differences in epitope recognition","volume":"19","author":"James","year":"2007","journal-title":"Int Immunol"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0170","doi-asserted-by":"crossref","first-page":"6665","DOI":"10.4049\/jimmunol.166.11.6665","article-title":"Tetramer\u2010guided epitope mapping: rapid identification and characterization of immunodominant CD4+ T cell epitopes from complex antigens","volume":"166","author":"Novak","year":"2001","journal-title":"J Immunol"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0175","series-title":"Immunobiology of the Human MHC: Proceedings of the 13th International Histocompatibility Workshop and Conference","first-page":"653","article-title":"Single Locus Polymorphism of Classical HLA Genes","author":"Meyer","year":"2007"},{"issue":"S1","key":"10.1111\/j.1538-7836.2011.04202.x_bb0180","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/j.seminhematol.2003.11.016","article-title":"Environmental and genetic factors influencing inhibitor development","volume":"41","author":"Oldenburg","year":"2004","journal-title":"Semin Hematol"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0185","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood-2005-09-3918","article-title":"Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A","volume":"107","author":"Astermark","year":"2006","journal-title":"Blood"},{"issue":"S2","key":"10.1111\/j.1538-7836.2011.04202.x_bb0190","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1055\/s-2006-946909","article-title":"Inhibitor development in hemophiliacs: the roles of genetic versus environmental factors","volume":"32","author":"Lee","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0195","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2006-05-024711","article-title":"Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A","volume":"108","author":"Astermark","year":"2006","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0200","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1111\/j.1538-7836.2007.02591.x","article-title":"Factor VIII (FVIII) gene mutations in 120 patients with hemophilia A: detection of 26 novel mutations and correlation with FVIII inhibitor development","volume":"5","author":"Repess\u00e9","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0205","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1111\/j.1538-7836.2009.03636.x","article-title":"Impact of polymorphisms of the major histocompatibility complex class II, interleukin\u201010, tumor necrosis factor\u2010\u03b1 and cytotoxic T\u2010lymphocyte antigen\u20104 genes on inhibitor development in severe hemophilia A","volume":"7","author":"Pavlova","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0210","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1055\/s-0029-1245105","article-title":"The multifactorial etiology of inhibitor development in hemophilia: genetics and environment","volume":"35","author":"Gouw","year":"2009","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0215","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1365-2516.2010.02231.x","article-title":"Non\u2010genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report","volume":"16","author":"Astermark","year":"2010","journal-title":"Haemophilia"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0220","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2516.2009.02150.x","article-title":"Polymorphisms in genes involved in autoimmune disease and the risk of FVIII inhibitor development in Italian patients with haemophilia A","volume":"16","author":"Bafunno","year":"2010","journal-title":"Haemophilia"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0225","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1182\/blood-2009-01-200725","article-title":"Lineages of human T\u2010cell clones, including T helper 17\/T helper 1 cells, isolated at different stages of anti\u2010factor VIII immune responses","volume":"114","author":"Ettinger","year":"2009","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0230","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1172\/JCI200423395","article-title":"CD4+ Tregs and immune control","volume":"114","author":"Feh\u00e9rvari","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0235","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1160\/TH06-09-0519","article-title":"Cytokine production by CD4+ T cells specific for coagulation factor VIII in healthy subjects and haemophilia A patients","volume":"97","author":"Hu","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0240","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1182\/blood-2008-04-151597","article-title":"Anti\u2010CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+\u2003CD25+dependent mechanism and by shifting cytokine production to favor a Th1 response","volume":"113","author":"Waters","year":"2009","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0245","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1055\/s-0037-1613257","article-title":"Distribution of Th1\u2010 and Th2\u2010induced anti\u2010factor VIII IgG subclasses in congenital and acquired hemophilia patients","volume":"88","author":"Reding","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0250","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0092-8674(93)90306-B","article-title":"Promiscuous and allele\u2010specific anchors in HLA\u2010DR\u2010binding peptides","volume":"74","author":"Hammer","year":"1993","journal-title":"Cell"},{"key":"10.1111\/j.1538-7836.2011.04202.x_bb0255","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/j.1538-7836.2005.01375.x","article-title":"Cellular immune responses in hemophilia: why do inhibitors develop in some, but not all hemophiliacs?","volume":"3","author":"White","year":"2005","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1538-7836.2011.04202.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622075912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622075912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1538-7836.2011.04202.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:58:00Z","timestamp":1761533880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622075912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S1538783622075912"],"URL":"https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04202.x","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T\u2010cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04202.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}